相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
Florian Moik et al.
BLOOD (2021)
Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience
L. Gutierrez-Sainz et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2021)
Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival
Tamara A. Sussman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors
Tariq Kewan et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2021)
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors
Oded Icht et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy
Deniz Can Guven et al.
SUPPORTIVE CARE IN CANCER (2021)
Increased incidence of venous thromboembolism with cancer immunotherapy
Joanna Roopkumar et al.
MED (2021)
Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors
Yosuke Ando et al.
INVESTIGATIONAL NEW DRUGS (2020)
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients
Federico Nichetti et al.
CANCERS (2020)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
Ryo Sato et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Myeloid cell-synthesized coagulation factor X dampens antitumor immunity
Claudine Graf et al.
SCIENCE IMMUNOLOGY (2019)
Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study
Jair Bar et al.
EUROPEAN JOURNAL OF CANCER (2019)
Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management
Florian Scotte et al.
CANCERS (2019)
Targeting myeloid-derived suppressor cells for cancer immunotherapy
Yijun Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Arterial thrombosis and anti-PD-1 blockade
Celine Boutros et al.
EUROPEAN JOURNAL OF CANCER (2018)
Frequency, risk actors, and impact on mortality of arterial thromboembolism in patients with cancer
Ella Grilz et al.
HAEMATOLOGICA (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Frequency, risk actors, and impact on mortality of arterial thromboembolism in patients with cancer
Ella Grilz et al.
HAEMATOLOGICA (2018)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer
Koji Haratani et al.
JAMA ONCOLOGY (2018)
Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab
Richard P. Tobin et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Venous Thromboembolism in Cancer Patients Receiving Immunotherapy
Joanna Roopkumar et al.
BLOOD (2018)
Risk of Arterial Thromboembolism in Patients With Cancer
Babak B. Navi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Shunsuke Teraoka et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Coagulation and fibrinolysis in gastric cancer
Ombretta Repetto et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2017)
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis
Yang-Bo Hu et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis
A. C. Foks et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Carlos Alfaro et al.
CLINICAL CANCER RESEARCH (2016)
Immune suppressive mechanisms in the tumor microenvironment
David H. Munn et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Dangerous liaisons: complement, coagulation, and kallikrein/kinin cross-talk act as a linchpin in the events leading to thromboinflammation
Kristina N. Ekdahl et al.
IMMUNOLOGICAL REVIEWS (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity
Janette Bester et al.
SCIENTIFIC REPORTS (2016)
Macrophages and Therapeutic Resistance in Cancer
Brian Ruffell et al.
CANCER CELL (2015)
Venous thromboembolism risk prediction in ambulatory cancer patients: Clinical significance of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio
Patrizia Ferroni et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
PARP-14 combines with tristetraprolin in the selective posttranscriptional control of macrophage tissue factor expression
M. Bilal Iqbal et al.
BLOOD (2014)
The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: A potential therapeutic opportunity for atherosclerotic thrombosis
Pengfei Jiang et al.
THROMBOSIS RESEARCH (2014)
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score
Melina Verso et al.
INTERNAL AND EMERGENCY MEDICINE (2012)
Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases
Gladys Alvarado et al.
MELANOMA RESEARCH (2012)
High prevalence and risk factors of thromboembolism in stage IV melanoma
A. Sparsa et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2011)
Characterization of the MDSC Proteome Associated with Metastatic Murine Mammary Tumors Using Label-Free Mass Spectrometry and Shotgun Proteomics
Angela M. Boutte et al.
PLOS ONE (2011)
Prediction of venous thromboembolism in cancer patients
Cihan Ay et al.
BLOOD (2010)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Role of Tissue Factor in Cancer
Raj S. Kasthuri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Development and validation of a predictive model for chemotherapy-associated thrombosis
Alok A. Khorana et al.
BLOOD (2008)
Trousseau's syndrome: Multiple definitions and multiple mechanisms
Ajit Varki
BLOOD (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma
JW Blom et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
P Prandoni et al.
BLOOD (2002)
分享论文
